fda glp-1 warning september 2025 letters compounded Fda Warning Letters Glp- 1 Compounded September 2025 There's lots going on this month at FDA fda glp-1 compounding warning letters

Give side effects time to improve

Food and Drug Administration and is approved for commercial use in several countries including Japan, Mexico, Singapore, and South Korea

Zhang Y, Chen ZJ, Zhao H

Severe or progressive muscle weakness that interferes with daily activitiessuch as difficulty climbing stairs, rising from a chair, or lifting objectsrequires medical assessment

The drugs strong selectivity allows for higher doses while minimizing off-target effects for sustained inhibition of its targets

Its 2020 and 2021 guidance documents on Orange Book patent listing made clear that only patents claiming the approved drug itself or its approved method of use may be listed [5]